Fireside Chat: Evaluating Solid-Phase, Enzymatic, & Liquid-Phase Synthesis Routes to Enable Scalable & Sustainable Oligonucleotide Production

• Comparing yield efficiency, impurity formation profiles, and sequence-length constraints across different phase oligo platforms
• Assessing platform readiness for GMP control, stereochemical management, and regulatory acceptance when introducing alternative synthesis technologies
• Determining when transitioning synthesis routes materially improves long-term scalability and manufacturing flexibility

Speakers:

Hagen Cramer

CTO

QurAlis Corp.

Paul Peng

Vice President, CMC

City Therapeutics